about
Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patientsSOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.Recent advances in our understanding of giant cell arteritis pathogenesis.Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling.Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients.SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma.Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis.Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis.Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis.Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study.Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways.Authors’ response to the eLetter by Moiseevet alFunctionally Relevant Treg Cells Are Present in Giant Cell Arteritis Lesions: Comment on the Article by Samson et alIncreased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritisLIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy
P50
Q36150929-11FFD1AC-88D8-4F9A-BBB5-0C31246C0EEFQ38702669-17DF8E58-893C-4279-9BBF-225B2940EAD8Q39341667-1DBD6E6C-2956-4631-9D13-45C7B0AEE870Q39918063-4156FDC0-87C9-4CD5-BB15-536E0D395C90Q47104190-2396821C-4035-4C70-8F16-91111DD112DBQ48284944-B013B82D-762E-4382-B14C-858BD6839B60Q50948184-CA3BEF6C-1045-4354-B04F-2DAD6DC66783Q51033475-8C627376-DDE6-4135-849D-4F3E6FC4B48AQ52893205-74A220B5-5E21-42F4-8B3D-A98E589C4523Q53073312-667A7472-8C7C-47C1-9EB6-7C87ED784172Q54943677-F001F43D-B063-4E6E-9C4B-AC5353E8943BQ61914150-9512F382-54AC-45D3-8312-6143C01E9998Q61914168-157A19BA-38C1-4A07-9979-2914CBE4A20EQ61914171-B6854206-059B-450A-82B2-D4A56B7D891FQ92666770-DD154C47-1853-42D9-9AFE-22B9CC335577
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ester Planas-Rigol
@ast
Ester Planas-Rigol
@en
Ester Planas-Rigol
@es
Ester Planas-Rigol
@nl
type
label
Ester Planas-Rigol
@ast
Ester Planas-Rigol
@en
Ester Planas-Rigol
@es
Ester Planas-Rigol
@nl
prefLabel
Ester Planas-Rigol
@ast
Ester Planas-Rigol
@en
Ester Planas-Rigol
@es
Ester Planas-Rigol
@nl
P108
P106
P108
P31
P496
0000-0001-5948-2241